A new microsample coagulation analyzer (Hemochron® Jr.) has recently been developed which performs a modified activated clotting time (ACT +) and an aPTT by using different reagents. The Hemochron® Jr. measures the clotting time of a 5-microliter whole-blood sample by an optical detector and extrapolates the results to the activated clotting time (ACT+) or the plasmaactivated partial thromboplastin time by using a validated regression analysis. We compared 124 simultaneous ACT+ and Hemochron® ACTs, and 53 paired Hemochron® Jr. aPTTs and hospital laboratory aPTTs, in 44 patients during coronary intervention. The Hemochron® Jr. aPTT closely correlated with the lab aPTT (r = .79, P < .0001), and the test results were available much more rapidly than the lab aPTT (3.5 ± 1.1 vs. 56.3 ± 25.5 min, P=0.0029). A comparison of duplicate ACT+ measurements did not identify a significant difference in the means (292 ± 115 sec vs. 293 ± 112 sec, P=0.72). The ACT+ closely correlated with the Hemochron® ACTs (r = .85, P < .0001). At baseline, the mean ACT+ (175 ± 43 sec) exceeded the Hemochron® ACT (144 ± 36 sec) by 22% (P < .001). After heparin administration, the mean ACT+ (378 ± 74 sec) exceeded the Hemochron® ACT (332 ± 65) by 12% (P < .001). The Hemochron® Jr. provides a fast and reproducible methodology for measuring ACT and aPTT, using a small blood volume. Further studies are required to determine the optimal anticoagulation range when using the Hemochron® Jr. during or after interventional procedures.
|Original language||English (US)|
|Number of pages||6|
|Journal||Catheterization and cardiovascular diagnosis|
|State||Published - Sep 1996|
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine